Je was op zoek naar: valdecoxib (Engels - Deens)

kudeq valdecoxib
kudeq valdecoxib part b

• bextra • valdecoxib
bextra valdecoxib part b

valdecoxib pharmacia europe eeig valdecoxib
valdecoxib pharmacia europe eeig valdecoxib part b

valdecoxib is not removed by haemodialysis.
valdecoxib fjernes ikke ved hæmodialyse.

valdecoxib-pfizer europe eeig valdecoxib
valdecoxib- pfizer europe eeig valdecoxib part b

· part b· kudeq · valdecoxib · part b
kudeq valdecoxib part b

celecoxib, parecoxib, valdecoxib, rofecoxib, etoricoxib
celecoxib, parecoxib, valdecoxib, rofecoxib, etoricoxib

this means that it is converted to valdecoxib in the body.
det betyder, at stoffet omdannes til valdecoxib i kroppen.

parecoxib is rapidly hydrolysed to the active metabolite valdecoxib.
parecoxib hydrolyseres hurtigt til den aktive metabolit valdecoxib.

valdecoxib, but not parecoxib, is extensively partitioned into erythrocytes.
valdecoxib, men ikke parecoxib, fordeles i stor udstrækning til erytrocytterne.

it is not known whether valdecoxib is excreted in human milk.
det vides ikke, om valdecoxib udskilles i modermælken hos mennesker.

celecoxib, parecoxib, valdecoxib, rofecoxib, etoricoxib cerivastatin bupropion felodipine
rofecoxib, etoricoxib cerivastatin

· bextra · valdecoxib · part b· valdyn · valdecoxib · part b
valdyn valdecoxib part b

exposure to valdecoxib was similar in terms of auc and cmax following iv and im administration.
eksponeringen for valdecoxib var sammenlignelig med hensyn til både auc og cmax efter i. v. og i. m. administration.efter i. v. eller i. m. administration var eksponering af valdecoxib ens, udtrykt i auc og cmax.

- the data on valdecoxib and parecoxib presented in the cabg (coronary artery bypass
- oplysningerne om valdecoxib og parecoxib i cabg - (koronararterie- bypass

steady state plasma concentrations of valdecoxib were reached within 4 days with twice daily dosing.
valdecoxibs steady state plasmakoncentrationer nås inden for 4 dage ved dosering 2 gange dagligt.

on 20 april 2005, pfizer presented data on serious skin reactions for valdecoxib during a hearing.
den 20. april 2005 fremlagde pfizer under en høring oplysninger om alvorlige hudreaktioner i forbindelse med valdecoxib.

valdecoxib is eliminated via hepatic metabolism with less than 5% unchanged valdecoxib recovered in the urine.
valdecoxib udskilles via levermetabolisme, og mindre end 5% uomdannet valdecoxib genfindes i urinen.

elimination valdecoxib is eliminated via hepatic metabolism with less than 5% unchanged valdecoxib recovered in the urine.
elimination valdecoxib udskilles via levermetabolisme, og mindre end 5% uomdannet valdecoxib genfindes i urinen.

valdecoxib is a selective cyclooxygenase-2 (cox-2) inhibitor within the clinical dose range.
valdecoxib er inden for det kliniske dosisinterval en oral, selektiv cyclooxygenase- 2 (cox- 2) hæmmer.